or Try an Advanced Search...

    Technical Analysis for PBLA - Panbela Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.40 -2.20% -0.01
    PBLA closed down 0.29 percent on Monday, May 6, 2024, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical PBLA trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction -2.20%
    Narrow Range Bar Range Contraction -2.20%
    Wide Bands Range Expansion -2.20%
    20 DMA Resistance Bearish -2.49%
    Earnings Movers Other -2.49%
    Inside Day Range Contraction -2.49%
    Wide Bands Range Expansion -2.49%
    Gapped Up Strength -2.49%
    New 52 Week Closing Low Bearish 4.90%
    Earnings Movers Other 4.90%
    Older End-of-Day Signals for PBLA ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 3 hours ago
    Down 3% about 3 hours ago
    Fell Below Previous Day's Low about 3 hours ago
    Down 2 % about 3 hours ago
    Down 1% about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PBLA Chart by TradingView
    Basic chart:

    Profile

    Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents and in treating other types of cancer.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Pancreatic Cancer Carcinoma Gastrointestinal Cancer Mm 151

    Is PBLA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 6 Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
    May 1 Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
    Apr 30 Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
    Apr 22 Panbela Therapeutics announces delay of expected data from pancreatic cancer treatment trial
    Apr 22 Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
    Apr 18 Panbela Announces Poster Presentation at American Association for Cancer Research:
    Apr 16 Panbela Announces Transfer to OTCQB Market
    Mar 27 Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
    Mar 26 Panbela Therapeutics GAAP EPS of -$65.90 beats by $151.10
    Mar 26 Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
    See more PBLA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 250.5
    52 Week Low 0.35
    Average Volume 165,229
    200-Day Moving Average 13.84
    50-Day Moving Average 0.65
    20-Day Moving Average 0.47
    10-Day Moving Average 0.42
    Average True Range 0.10
    RSI (14) 34.64
    ADX 31.32
    +DI 13.17
    -DI 17.49
    Chandelier Exit (Long, 3 ATRs) 0.34
    Chandelier Exit (Short, 3 ATRs) 0.64
    Upper Bollinger Bands 0.59
    Lower Bollinger Band 0.34
    Percent B (%b) 0.27
    BandWidth 53.93
    MACD Line -0.11
    MACD Signal Line -0.14
    MACD Histogram 0.0286
    Fundamentals Value
    Market Cap 1.42 Million
    Num Shares 3.48 Million
    EPS -157.02
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 3.22
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.46
    Resistance 3 (R3) 0.46 0.44 0.45
    Resistance 2 (R2) 0.44 0.42 0.44 0.45
    Resistance 1 (R1) 0.42 0.41 0.43 0.43 0.45
    Pivot Point 0.40 0.40 0.41 0.40 0.40
    Support 1 (S1) 0.39 0.39 0.40 0.39 0.37
    Support 2 (S2) 0.37 0.38 0.37 0.37
    Support 3 (S3) 0.35 0.37 0.37
    Support 4 (S4) 0.36